Evidence map›Paper›PMID 29721125›Full record

ArticleRadiology case reports2018

Contrast-enhanced ultrasound identifies early extrahepatic collateral contributing to residual hepatocellular tumor viability after transarterial chemoembolization.

Sriharsha Gummadi, Maria Stanczak, Andrej Lyshchik, Flemming Forsberg, Colette M Shaw, John R Eisenbrey

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sriharsha GummadiDepartment of Surgery, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
Maria StanczakDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Andrej LyshchikDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Flemming ForsbergDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Colette M ShawDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
John R EisenbreyDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Thomas Jefferson University · US

Funding

2D and 3D Contrast-enhanced Ultrasound Evaluation of HCC ChemoembolizationR01CA194307 · NCI · THOMAS JEFFERSON UNIVERSITY · PI John Eisenbrey · 2016 to 2026
$5.3M
NCI NIH HHS R01 CA194307
6 · The paper itself

Abstract

The mainstay of treatment for unresectable hepatocellular carcinoma is locoregional therapy including percutaneous ablation and transarterial chemo- and radioembolization. While monitoring for tumor response after transarterial chemoembolization is crucial, current imaging strategies are suboptimal. The standard of care is contrast-enhanced magnetic resonance imaging or computed tomography imaging performed at least 4 to 6 weeks after therapy. We present a case in which contrast-enhanced ultrasound identified a specific extra-hepatic collateral from the gastroduodenal artery supplying residual viable tumor and assisting with directed transarterial management.

Indexed as

Contrast-enhanced ultrasoundHepatocellular carcinomaTransarterial chemoembolization

Identifiers

PMID29721125
PMCPMC5930180
OpenAlexW2799577593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.